Ahmar U. Zaidi/LinkedIn
Jun 14, 2026, 18:01
Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
Ahmar U. Zaidi, Senior Medical Director of Clinical Development at Agios Pharmaceuticals, shared a post on LinkedIn:
“EHA plenary for the RISE UP study!
An incredible moment.
Not because the RISE UP study was on one of the biggest stages in hematology, but because of what it represented.
The first pivotal study of a new mechanism in Sickle Cell disease. The chance to help tell the story of a potential new treatment paradigm in sickle cell disease: PK activation.
There is immense gratitude for the patients, families, investigators, advocates, and colleagues who made this moment possible.
Progress in sickle cell disease belongs to all of them.
I am simply fortunate to be here while their story is told.”
Stay updated with Hemostasis Today.
-
Aug 7, 2026, 16:26Shayan Mohammadmoradi: Excited to Co-Chair the 2028 Hemostasis Gordon Research Seminar
-
Aug 7, 2026, 16:04Ayuka King-Percival: Understanding Platelet Aggregation Testing
-
Aug 7, 2026, 15:59Nita RadhakrishnanÖ‰ New Evidence-Based Guidelines for Transfusion-Dependent Thalassemia
-
Aug 7, 2026, 15:54Seema Dawood: Why the Peripheral Blood Smear Still Matters in the Age of Automation?
-
Aug 7, 2026, 15:42Mohammed Elmourtada AbdulgayoomÖ‰ Caplacizumab-Enabled Treatment of iTTP Without Plasma Exchange
-
Aug 7, 2026, 15:40Renata Evertz: THUNDER Study Sets a New Benchmark in Stroke Thrombectomy
-
Aug 7, 2026, 15:23Ashley Brown: An Incredible Week at the Hemostasis GRC
-
Aug 7, 2026, 15:04Danique Steeghs: Developing a Chip-Sized ADAMTS13 Activity Assay for TTP Point-of-Care Testing
-
Aug 7, 2026, 15:02Mohd Laraib: The Importance of Multidisciplinary Collaboration in the Management of CAPS